EMA proposes approval of 10 new drugs

EMA recommends approval of 10 new medicines

The Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) recommended the approval of 10 medicines at its meeting in June 2024. These include Balversa (erdafitinib) for urothelial carcinoma and Eurneffy (epinephrine), the first nasal spray for allergic emergencies. Read more here

If you need more information on regulatory issues, ELS can certainly help.

Please do not hesitate to contact your local ELS consultant or via email info@elssolutions.pt

ELS Group

ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.